{"id":"NCT00383708","sponsor":"Ipsen","briefTitle":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","officialTitle":"Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2006-10-03","resultsPosted":"2018-07-23","lastUpdate":"2022-09-27"},"enrollment":125,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acromegaly"],"interventions":[{"type":"DRUG","name":"lanreotide (Autogel formulation)","otherNames":[]},{"type":"DRUG","name":"Pegvisomant","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The main aim of this study is to assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep sub-cutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via sub-cutaneous injection given once or twice a week) on IGF-1 levels over 28 weeks in acromegalic patients. The primary endpoint will be the percentage of acromegalic patients with normalised (age and sex adjusted) IGF-1 level at the end of the co-treatment period.","primaryOutcome":{"measure":"Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period","timeFrame":"V3 (Week 12; Baseline) up to V11 (Week 44)","effectByArm":[{"arm":"Lanreotide Autogel + Pegvisomant Co-administration","deltaMin":57.9,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":24,"countries":["Czechia","Denmark","France","Germany","Greece","Italy","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["21148630"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":57},"commonTop":["Diarrhoea","Cholelithiasis","Influenza","Nasopharyngitis","Diabetes mellitus"]}}